Regional molecular genetics centers in thoracic oncology: what and who should be tested?

Fabrice Barlési (1, 2) , Pascale Tomasini (1, 2) , Frédéric Fina (3) , Véronique Secq (4) , Laurent Greillier (1, 2) , Isabelle Nanni-Metellus (3) , Stéphane Garcia (4) , L'Houcine Ouafik (2, 3)

1 Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
2 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
3 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
4 service hospitalier d'anatomie et cytologie pathologique humaine, APHM, Marseille

Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.

Keywords: bioguided treatment; french NCI; lung cancer; molecular genetics center; molecular profiling; personalized therapy

Domains: Life Sciences [q-bio]; Cancer

Fabrice Barlési, Pascale Tomasini, Frédéric Fina, Véronique Secq, Laurent Greillier, et al.. Regional molecular genetics centers in thoracic oncology: what and who should be tested?. Bulletin du Cancer, 2013, 100 (7-8), pp.737-741. ⟨hal-01708071⟩